Category - Developments

Developments

MIT-led research team unveil oral insulin capsule for Type 2 diabetes

Researchers from the Massachusetts Institute of Technology, Brigham and Women’s Hospital and Novo Nordisk have come up with an oral insulin pill that could replace injections for patients with Type 2 diabetes, according...

February 11, 2019

Developments

IntelGenx to receive Japanese patent for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQX:IGXT) received a Decision to Grant notice from the Japanese Patent Office (JPO) for the VersaFilm formulation used in its thin oral film RIZAPORT product for the treatment of acute migraines...

February 11, 2019

Developments

FDA accepts Eyenovia IND for Phase 3 MicroPine trial of myopia in children

The FDA accepted Eyenovia’s (NASDAQ:EYEN) IND to initiate the Phase 3 CHAPERONE registration trial of its MicroPine treatment to reduce the progression of myopia in children. The CHAPERONE study is a U.S.-based, multi...

February 6, 2019

Developments

Ocutrx Vision named to StartUp City’s list of promising wearable startups

Closely-held Ocutrx Vision Technologies was named to StartUp City’s annual list of the 15 most promising wearable technology startups for its Oculenz AR (augmented reality) glasses for low vision patients. Oculenz is...

February 5, 2019

Developments

Titan Pharma posts double-digit increase in Probuphine shipments

Titan Pharmaceuticals (NASDAQ:TTNP) updated the U.S. commercial relaunch of its Probuphine implant for the treatment for opioid use disorder, reporting that it achieved a double-digit increase in product shipments in...

February 1, 2019

Developments

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

The FDA has performed a pre-approval inspection of IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Health Canada-certified cGMP manufacturing facility in Montreal in connection with the company’s NDA for RIZAPORT, a VersaFilm oral...

January 30, 2019

Developments

ArcherDX acquires genetic testing firm Baby Genes

Closely-held ArcherDX acquired genetic testing lab, Baby Genes. It will operate as a wholly-owned subsidiary under the name ArcherDX Clinical Services, and continue to market a suite of existing newborn genetic testing...

January 30, 2019

Developments

Lutronic Vision initiates preclinical laser trial for dry AMD

Closely-held Lutronic Vision initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). At the conclusion of the...

January 30, 2019

Developments

Triphase Accelerator options leukemia compound to Celgene

Closely-held Triphase Accelerator entered a new strategic partnership with Celgene (NASDAQ:CELG) to develop a preclinical therapeutic compound, TRPH-395, for the treatment of leukemia and other blood cancers...

January 29, 2019

Developments

IntelGenx updates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). To date, seven study sites across Canada have randomized eight subjects...

January 23, 2019

Category - Developments

MIT-led research team unveil oral insulin capsule for Type 2 diabetes

IntelGenx to receive Japanese patent for RIZAPORT VersaFilm

FDA accepts Eyenovia IND for Phase 3 MicroPine trial of myopia in children

Ocutrx Vision named to StartUp City’s list of promising wearable startups

Titan Pharma posts double-digit increase in Probuphine shipments

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

ArcherDX acquires genetic testing firm Baby Genes

Lutronic Vision initiates preclinical laser trial for dry AMD

Triphase Accelerator options leukemia compound to Celgene

IntelGenx updates Phase 2a Montelukast VersaFilm trial in AD

General

More